ETF Performance Overview: The Fidelity MSCI Health Care Index ETF (FHLC) has an implied analyst target price of $78.46, indicating a potential upside of 12% from its current trading price of $70.06.
Notable Holdings with Upside: Key underlying holdings of FHLC, such as MoonLake Immunotherapeutics (MLTX), Prestige Consumer Healthcare Inc (PBH), and AtriCure Inc (ATRC), show significant upside potential based on analyst target prices, with MLTX expected to rise by 77.88%, PBH by 35.21%, and ATRC by 34.73%.
Analyst Target Justification: The article raises questions about whether analysts' target prices are justified or overly optimistic, suggesting that high targets could lead to downgrades if they do not align with recent developments in the companies or industry.
Investor Research Recommendation: Investors are encouraged to conduct further research to assess the validity of the analysts' targets and to understand the implications of the current market conditions on these price predictions.
Wall Street analysts forecast PBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBH is 77.00 USD with a low forecast of 71.00 USD and a high forecast of 88.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast PBH stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PBH is 77.00 USD with a low forecast of 71.00 USD and a high forecast of 88.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 67.730
Low
71.00
Averages
77.00
High
88.00
Current: 67.730
Low
71.00
Averages
77.00
High
88.00
Scotiabank
Sector Perform
to
Outperform
upgrade
$99 -> $120
2025-12-18
Reason
Scotiabank
Price Target
$99 -> $120
AI Analysis
2025-12-18
upgrade
Sector Perform
to
Outperform
Reason
Scotiabank upgraded Premium Brands to Outperform from Sector Perform with a price target of C$120, up from C$99. The firm cites merger synergies, expectants for meaningful de-leverage over the next 6-12 months, and the company's exposure to stronger consumer spending growth in the U.S. in 2026 for the upgrade.
TD Securities
NULL -> Buy
maintain
$145 -> $160
2025-12-18
Reason
TD Securities
Price Target
$145 -> $160
2025-12-18
maintain
NULL -> Buy
Reason
TD Securities raised the firm's price target on Premium Brands to C$160 from C$145 and keeps a Buy rating on the shares.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for PBH
Unlock Now
Canaccord
Buy
maintain
$116 -> $123
2025-12-18
Reason
Canaccord
Price Target
$116 -> $123
2025-12-18
maintain
Buy
Reason
Canaccord raised the firm's price target on Premium Brands to C$123 from C$116 and keeps a Buy rating on the shares.
Stifel
Buy
maintain
$106 -> $111
2025-12-18
Reason
Stifel
Price Target
$106 -> $111
2025-12-18
maintain
Buy
Reason
Stifel raised the firm's price target on Premium Brands to C$111 from C$106 and keeps a Buy rating on the shares.
About PBH
Prestige Consumer Healthcare Inc. is a consumer healthcare products company. The Company is engaged in the development, manufacturing, marketing, sales and distribution of over-the-counter (OTC) health and personal care products to mass merchandisers, drug, food, dollar, convenience, club stores and e-commerce channels in North America (the United States and Canada) and in Australia and certain other international markets. Its segments include North American OTC Healthcare and International OTC Healthcare. Its diverse portfolio of brands includes Monistat and Summer’s Eve women's health products, BC and Goody's pain relievers, Clear Eyes and TheraTears eye care products, DenTek specialty oral care products, Dramamine motion sickness treatments, Fleet enemas and glycerin suppositories, Chloraseptic and Luden's sore throat treatments and drops, Compound W wart removal products, Boudreaux’s Butt Paste diaper rash ointments, Nix lice treatment products, Debrox earwax remover, and others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
